MEK inhibitors showed no clear difference in overall survival† compared with chemotherapy (low certainty).
MEK inhibitors probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
MEK inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
MEK inhibitors probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
BRAF plus MEK inhibitors leads to lower overall survival† compared with BRAF inhibitors (high certainty).
BRAF plus MEK inhibitors probably leads to lower progression‐free survival† compared with BRAF inhibitors (moderate certainty).
BRAF plus MEK inhibitors leads to higher tumour response compared with BRAF inhibitors (high certainty).
BRAF plus MEK inhibitors showed no clear difference in toxicity (≥ G3) compared with BRAF inhibitors (moderate certainty).